{"id":"W2754917529","doi":"10.1007/s00125-017-4430-0","title":"Bladder cancer in the EMPA-REG OUTCOME trial","year":2017,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"Novo Nordisk; Intarcia Therapeutics; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"EMPA; Empagliflozin; Human physiology; Medicine; Cancer; Diabetes mellitus; Internal medicine; Bladder cancer; Oncology; Type 2 diabetes; Endocrinology; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002631072,0.0004586249,0.001052473,0.0001476659,0.0001340771,0.00007574751,0.0006430537,0.001012566,0.0009768186],"category_scores_gemma":[0.0001570113,0.0002613423,0.0003349462,0.0001011319,0.0002025345,0.00005888141,0.00006388155,0.002118755,0.0002081593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000186321,"about_ca_system_score_gemma":0.0003305808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008792759,"about_ca_topic_score_gemma":0.0001425014,"domain_scores_codex":[0.9976652,0.0001731126,0.0004506808,0.0005570863,0.0005117229,0.0006421932],"domain_scores_gemma":[0.9981892,0.0001792364,0.000265662,0.001255705,0.00005774358,0.00005243095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001166049,0.0001142543,0.04918785,0.000101902,0.0003352876,0.001923461,0.0001908124,2.024035e-7,0.000002799476,0.00000434562,0.9438675,0.003105537],"study_design_scores_gemma":[0.0354598,0.0006025793,0.05400746,0.0001674526,0.0009040922,0.00003542955,0.00002913131,0.000001889167,0.00004128112,0.0001736797,0.9081655,0.0004116666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.06047164,0.002234849,0.000001380006,0.9090305,0.003411355,0.0028964,0.0003631822,0.00009373344,0.02149699],"genre_scores_gemma":[0.1378337,0.000211471,0.00002237773,0.8304983,0.01065981,0.001418891,0.0003677615,0.00009994462,0.0188878],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.07853218,"threshold_uncertainty_score":0.9999839,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07815138698429328,"score_gpt":0.3762121577773796,"score_spread":0.2980607707930863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}